Anavex Life Sciences Corp (AVXL)

[JWC3]

Might want to point out that the $200k-600k per patient price for A-273 is for the initial cost which shows incredibly high development costs. Initially the relatively RARE DISEASE, Rett Syndrome is the first and only indication approved and priced. Perhaps a year after this price is established ANAVEX will probably get ALZHEIMERS DISEASE approval. This may result in a lower price, but will undoubtedly see an INCREASE OF FOUR TO SIX ORDERS OF MAGNITUDE in the number of customer patients! So maybe the price for ALZ Patient could drop to $50K, well below that charged by a BP company!